Loading
Life sciences · Journal article
Journal of Pain & Palliative Care Pharmacotherapy · October 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Supportive oncology improves quality of life and symptom control for patients with cancer. This retrospective cohort analysis compared adjuvant analgesic therapies across three ambulatory settings at a Midwest health system: the standard care models, including physician-led primary oncology and advanced practice provider–led supportive oncology (APP-SO), vs. an interprofessional collaborative practice supportive oncology (IPCP-SO) model with an integrated palliative care clinical pharmacist. The primary objective was to compare the median number of therapeutic adjuvants; secondary objectives were pain control and oral morphine equivalents (OME). Patients were 18 years or older with stage 3 or 4 cancer, cancer-related pain, and cancer-directed treatment. Random sampling yielded 75 patients per group (N = 225) from 2019–2025 records. Groups had comparable baseline characteristics (p >.05). IPCP-SO was associated with more adjuvants than physician-led primary oncology (incidence rate ratio [IRR] 8.17, 95% CI: 5.19–12.87, p <.001) and APP-SO (IRR 2.02, 95% CI: 1.52–2.69, p <.001). Median clinic-visit numeric rating scale reduction was 1 point in the standard-model cohorts and 3 points in IPCP-SO. Median last-visit OME was lowest in physician-led primary oncology. IPCP-SO was associated with greater adjuvant use and greater pain reduction than APP-SO and physician-led primary oncology.